OCUGEN INC(NASDAQ:OCGN) stock News

OCGN Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Chartmill

Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows

2 days ago - By: Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

2 days ago - By: Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

2 days ago - By: Ocugen

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

2 days ago - By: Ocugen

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

6 days ago - By: Ocugen

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

6 days ago - By: Ocugen

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

11 days ago - By: Benzinga

Demystifying Ocugen: Insights From 5 Analyst Reviews

13 days ago - By: The Motley Fool

Ocugen (OCGN) Q2 Revenue Jumps 20%

14 days ago - By: Zacks Investment Research - Mentions: CCCC

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

14 days ago - By: Ocugen

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

14 days ago - By: Ocugen

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

14 days ago - By: Benzinga

A Peek at Ocugen's Future Earnings

25 days ago - By: Ocugen

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

25 days ago - By: Ocugen

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

a month ago - By: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

a month ago - By: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

a month ago - By: Ocugen

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

a month ago - By: Ocugen

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

2 months ago - By: Brodsky & Smith LLC - Mentions: CARM GNTY GBCI MRC ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

2 months ago - By: Ocugen - Mentions: CARM

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

2 months ago - By: Ocugen

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

2 months ago - By: Ocugen

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

2 months ago - By: Ocugen

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

2 months ago - By: Ocugen

Ocugen To Present at BIO International Convention 2025

2 months ago - By: Ocugen

Ocugen To Present at BIO International Convention 2025

2 months ago - By: Ocugen

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

2 months ago - By: Ocugen

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

3 months ago - By: Ocugen

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

3 months ago - By: Ocugen

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

3 months ago - By: Ocugen

Ocugen Provides Business Update with First Quarter 2025 Financial Results

3 months ago - By: Ocugen

OCUGEN INC (OCGN) Stock News

OCGN Latest News, Press Relases and Analysis